Cologuard® Wins Popular Science Magazine’s 2014 “Best of What’s New” Award

Cologuard® Wins Popular Science Magazine’s 2014 “Best of What’s New” Award

Exact Sciences announced Cologuard has received a 2014 “Best of What’s New” award from Popular Science.

Cologuard is the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Approved by the FDA in August, Cologuard detects the presence of cancer and precancer by analyzing both DNA and blood in the stool.

“Exact Sciences is honored to receive this recognition from the editors of Popular Science,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “The ‘Best of What’s New’ list recognizes the groundbreaking potential of Cologuard to improve the colon cancer screening rates and enable survival from a disease that is often considered the most preventable, yet least prevented cancer due to the lack of patient compliance with screening.”

Colorectal cancer is highly treatable with early detection through screening. However, 23 million Americans between 50 and 75 are not getting screened as recommended and, as a result, colorectal cancer remains the second-leading cancer killer in the United States. For those whose cancer is detected at an earlier stage, the five-year survival rate can be greater than 90 percent.

Cologuard, which is available by prescription, offers people 50 years and older, who are at average risk for colorectal cancer, an easy to use screening test, which they can do in the privacy of their own home. Cologuard has been proven to find 92 percent of colorectal cancers in average risk patients with 87 percent specificity. Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test. It is the first noninvasive screening test for colorectal cancer that analyzes both stool-based biomarkers including DNA and blood to detect cancer and precancer.

Each year, editors of Popular Science review thousands of new products and innovations of the year and choose the top 100 winners across 12 categories for inclusion in their annual “Best of What’s New” issue. To win, a product or technology must represent a significant step forward in its category. All of the winners are featured on the Popular Science website, and in the special Popular Science December issue.

About Exact Sciences Corp.

Exact Sciences Corp. (EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Stool DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.